A spike virosome vaccine induces pan-sarbecovirus antibody responses in mice

Mitch Brinkkemper, Meliawati Poniman, Esther Siteur-van Rijnstra, Widad Ait Iddouch, Tom P. L. Bijl, Denise Guerra, Khadija Tejjani, Marloes Grobben, Farien Bhoelan, Denzel Bemelman, Ronald Kempers, Marit J. van Gils, Kwinten Sliepen, Toon Stegmann, Yme U. van der Velden, Rogier W. Sanders

Research output: Contribution to journalArticleAcademicpeer-review


Zoonotic events by sarbecoviruses have sparked an epidemic (severe acute respiratory syndrome coronavirus [SARS-CoV]) and a pandemic (SARS-CoV-2) in the past two decades. The continued risk of spillovers from animals to humans is an ongoing threat to global health and a pan-sarbecovirus vaccine would be an important contribution to pandemic preparedness. Here, we describe multivalent virosome-based vaccines that present stabilized spike proteins from four sarbecovirus strains, one from each clade. A cocktail of four monovalent virosomes or a mosaic virosome preparation induced broad sarbecovirus binding and neutralizing antibody responses in mice. Pre-existing immunity against SARS-CoV-2 and extending the intervals between immunizations enhanced antibody responses. These results should inform the development of a pan-sarbecovirus vaccine, as part of our efforts to prepare for and/or avoid a next pandemic.
Original languageEnglish
Article number109719
Issue number5
Publication statusPublished - 17 May 2024


  • Immunology
  • Virology

Cite this